Hims added oral and injectable TRT options. Understand provider review, product questions and why expanded access is not a treatment recommendation.
On October 21, 2026, Hims & Hers announced an expansion of its testosterone care to include injectable and oral testosterone replacement therapy, or TRT. The company said treatment requires lab testing and a prescription following provider assessment.
This article is for informational purposes only and is not medical advice.
Hims says the launch extends its existing enclomiphene-based care to include injectable and oral TRT. Reuters also reported the expansion into those treatment routes.
The change is in the range of treatments offered through the service. A man reviewing the announcement now encounters more than the company's previous approach to testosterone care. Whether any treatment is appropriate remains a separate provider decision.
The model combines at-home sample collection with telehealth review and prescription treatment. According to Hims, the provider reviews the customer's symptoms, health history and lab results before deciding whether treatment is medically appropriate.
That makes this an access story as well as a product announcement. The important distinction is between making a treatment available for consideration and recommending it to a particular person. Those are different decisions even when they appear within the same online service.
Hims describes a sequence with several parts. These are the company's stated service steps rather than instructions for diagnosing or treating low testosterone independently.
The sequence separates obtaining information from making a prescribing decision. Completing an intake or submitting a sample is not presented as an automatic commitment to TRT. The provider's review is the point at which the company says medical appropriateness is assessed.
Testostra's discussion of putting symptoms into clinical context offers further background for understanding that distinction. The useful question is how the reported symptoms and medical history fit with the lab findings, not simply whether a number has appeared on a screen.
Follow-up is also part of the company's description. Hims refers to follow-up labs and provider support as features of the service. These are relevant parts of its stated care model, alongside the initial test and prescription review.
Treatment routes are broad categories. A discussion about an injectable or an oral option still needs to identify the actual product being considered. One practical distinction raised by the announcement is whether the proposed treatment is compounded or commercially manufactured.
Separate coverage of the launch described an FDA-approved pill. That description should stay attached to the pill being discussed. It is not a basis for assuming that every treatment in an expanded service has the same approval status.
The product-level questions raised by this announcement include:
These questions keep the discussion focused on an identifiable treatment rather than a route label. An injection and a pill are not complete product descriptions. The company's description of an option is a starting point for that discussion, not a personal instruction to use it.
For readers considering access in their state, actual availability is another question to confirm with the service. A launch headline should not be treated as a promise that every option will be available to every person in every location.
Understanding the specific proposal also makes the next clinical conversation more concrete. The issue is not whether oral or injectable treatment sounds more convenient in general. It is which product the provider is considering and why it fits the assessment.
This announcement needs to be read according to the kind of evidence it contains. It is a company service launch rather than a clinical study reporting physiological results or a new medical guideline.
The service details come from Hims. Its chief operating officer Mike Chi described testing and support as ways to make the customer-provider relationship easier to start and sustain. That is an executive's account of the service's intended design, not independent evidence that it improves clinical outcomes.
Descriptions of convenience and ongoing support answer questions about how care is organized. They should not be substituted for evidence about the benefits or risks of a particular treatment. The distinction matters when a business announcement is read as health news.
Hims also cited a company-commissioned survey conducted by Culture Co-op. In that survey, 45% of respondents selected at least one listed low-testosterone treatment they were familiar with.
That result concerns familiarity among the surveyed participants. It is not an estimate of all men's treatment knowledge. It also does not show whether respondents needed TRT or whether any treatment would benefit them.
Familiarity and clinical eligibility are different questions. A survey about awareness helps explain how a company presents its market, but it does not provide evidence for an individual's prescribing decision.
The announcement does not give a single testosterone cutoff that independently determines eligibility. It places the decision with provider review of the person's symptoms, history and lab results. It also does not turn its service description into an individualized monitoring plan.
For readers comparing reports, understanding differences between testosterone tests is a related educational topic. A result belongs within the assessment described by the service rather than being treated as a standalone answer about treatment.
This announcement should not by itself change current medical practice. It expands the routes offered through one service. It does not replace the need for a clinician's assessment before prescribing or make TRT the default response to concerns about testosterone.
For someone evaluating the news, the practical outcome is a clearer set of questions for qualified care: what assessment supports treatment, which product is proposed and how follow-up will be handled. Those questions apply to the care decision rather than to the marketing language around the launch.
The company says its process includes intake, testing and licensed-provider review. The relevant standard for an individual remains whether the proposed treatment is medically appropriate after that review. More convenient access and a broader menu do not settle that question on their own.
Bottom line: the launch adds options to discuss, not a reason to begin or change treatment independently. Any decision about starting TRT or changing an existing prescription belongs with the treating clinician who can assess the person's full clinical situation.
Expanding access to TRT leaves a separate question about the evidence behind treatment, which Testostra addresses through clear hormone-health education. Men weighing a larger menu of options can use its coverage of TRT risks and monitoring to better understand the issues raised in clinical conversations without receiving a personal treatment recommendation.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra